Table 1 Baseline characteristics of study patients and lesions treated
Characteristics | TACE | SBRT | p value |
|---|---|---|---|
n = 367 | n = 35 | ||
Gender | 0.802 | ||
Male | 314 (85.6) | 29 (83) | |
Female | 53 (14.4) | 6 (17) | |
Age in years | 66.8 ± 9.2 | 69.0 ± 8.1 | 0.305 |
ECOG1 | |||
0 | 277 (75.5) | 23 (65.7) | 0.224 |
1 | 43 (11.7) | 12 (34.3) | 0.001 |
2 | 47 (12.8) | 0 | 0.023 |
Etiology of liver disease | 0.018 | ||
Viral | 114 (31.1) | 4 (11.4) | |
Non-viral | 253 (68.9) | 31 (88.6) | |
Child Score | 5.9 ± 1.3 | 6.4 ± 1.3 | 0.006 |
Child A | 269 (73.3) | 19 (4.3) | 0.020 |
Child B | 95 (25.9) | 16 (45.7) | 0.017 |
Child C | 3 (0.8) | 0 | 0.999 |
Previous treatmenta | 5 (1.3) | 29 (83.0) | < 0.001 |
None | 362 (98.6) | 6 (17.1) | < 0.001 |
Surgery | 2 (0.5) | 8 (22.9) | 0.899 |
Sorafenib | 2 (0.5) | 1(2.9) | 0.324 |
TACE | 1 (0.3) | 28(80.0) | < 0.001 |
Intrahepatic tumor expansion | 0.010 | ||
Oligonodular | 144 (39.2) | 6 (17) | |
Multifocal | 223 (60.8) | 29 (83) | |
BCLC2 | 0.046 | ||
B | 299 (81.5) | 24 (68.6) | |
C | 68 (18.5) | 11 (31.4) | |
Largest tumor diameter [cm] | 6.1 ± 3.4 | 8.4 ± 7.1 | 0.001 |
Segmental PVT4 | 68 (18.5) | 11 (31.4) | 0.076 |
Laboratory | |||
Platelets [103/μl] | 187 ± 115 | 183 ± 131 | 0.263 |
AST7 [U/l] | 90 ± 80 | 99 ± 66 | 0.238 |
ALT8 [U/l] | 66 ± 58 | 55 ± 40 | 0.335 |
Bilirubin [mg/dl] | 1.2 ± 1.2 | 1.8 ± 1.8 | 0.656 |
Albumin [g/dl] | 3.6 ± 0.6 | 3.4 ± 0.5 | 0.034 |
AFP15 [ng/ml] | 4792.4 ± 25,171.7 | 2279.8 ± 9386.5 | 0.493 |
Technical data TACE3 and SBRT5 | |||
TACE | |||
cTACE6 | 326 (88.8) | ||
Drug-eluting beads TACE | 41 (11.2) | ||
Number of TACE sessions | 2 ± 1 | ||
Two TACE | 253 (68.9) | ||
Three TACE | 84 (22.9) | ||
Four TACE | 30 (8.2) | ||
SBRT | median (IQR14) | ||
Total prescribed dose (TD) | 45 (42–50) Gy | ||
EQD210,TD9 | 56 (54–83) Gy | ||
Dmax10 | 53 (50–57) Gy | ||
EQD210,Dmax11 | 82 (62–98) Gy | ||
Dmean,liver 12 | 17 (14–25) Gy | ||
EQD2Dmean,liver 13 | 20 (14–36) Gy | ||